SCHEMBL20134749

SCHEMBL20134749

CC1(c2ccc(C(=O)O)cc2I)NC(=O)NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 1/20 0.39
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HSP90AA1 P07900 1/20 0.36
ESR2 Q92731 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
RARB P10826 5/20 0.36
RARG P13631 5/20 0.36
RARA P10276 4/20 0.36
CYP26A1 O43174 2/20 0.36
LMNA P02545 1/20 0.36
CYP26B1 Q9NR63 1/20 0.36
TPMT P51580 1/20 0.36
RXRA P19793 2/20 0.35
RXRB P28702 2/20 0.35
RXRG P48443 2/20 0.35
TDP2 O95551 1/20 0.35
TTR P02766 2/20 0.35
CA12 O43570 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688782 1.00 PTGER3 (0.39) PTGER3MEN1KMT2AHSP90AA1ESR2
SCHEMBL20135334 0.83 LMNA (0.42) PTGER3MEN1KMT2ARARBRARG
SCHEMBL29688911 0.83 LMNA (0.42) PTGER3MEN1KMT2ARARBRARG
SCHEMBL29688481 0.81 CA12 (0.50) RARBRARGRARALMNATPMT
SCHEMBL20134984 0.81 CA12 (0.50) RARBRARGRARALMNATPMT
SCHEMBL20134880 0.75 MEN1 (0.55) MEN1KMT2ALMNARXRA
SCHEMBL4308515 0.75 MEN1 (0.55) MEN1KMT2ALMNARXRA
SCHEMBL20135034 0.72 MEN1 (0.37) PTGER3MEN1KMT2ARARBRARG
SCHEMBL20135222 0.67 GRM1 (0.38) MEN1KMT2ATDP1RXRARXRB
SCHEMBL10263241 0.67 PTGER3 (0.34) PTGER3MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 PTGER3 224/4885MEN1 3735/4885KMT2A 2568/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 PTGER3 190/4885MEN1 2913/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.